Related Experiment Video
Updated: Jul 28, 2026
11:49
Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay
Published on: July 28, 2014
From basic research on neuropeptide receptors to clinical benefit
K R Oliver1, D J Sirinathsinghji, R G Hill
1Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
Drug News & Perspectives
|July 25, 2003
Summary
Neuropeptides and their receptors are promising drug targets. Modern methods accelerate the discovery of new neuropeptide targets for diverse clinical applications, offering significant therapeutic potential.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- Neuropeptide systems present unique characteristics compared to classic neurotransmitters, making them attractive for therapeutic targeting.
- Opioid receptor agonists exemplify successful neuropeptide receptor ligand-based drug development for pain management.
- Traditional drug discovery identified neuropeptides before their receptors, but modern approaches have reversed this trend.
Purpose of the Study:
- To provide an overview of neuropeptide research progress.
- To discuss current and potential clinical applications of targeting neuropeptide systems.
- To highlight the impact of modern methodologies on neuropeptide drug discovery.
Main Methods:
- Review of established and emerging methodologies in neuropeptide research.
- Analysis of bioinformatics, molecular, proteomic, and transgenic approaches.
- Examination of classic and modern strategies for target identification.
Main Results:
- Neuropeptide receptor antagonists for substance P, cholecystokinin, and neurotensin are under development.
- Modern technologies expedite the identification of novel receptor targets.
- Expanded knowledge of neuropeptide involvement in physiological and pathophysiological processes.
Conclusions:
- Neuropeptide systems offer significant opportunities for novel drug development.
- Advancements in technology are crucial for selecting and validating new therapeutic targets.
- Targeting neuropeptides holds promise for substantial clinical benefit across various indications.
Related Concept Videos
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...